LDR's ROI-C Cervical Cage receives expanded indication approval: 4 points

Written by Anuja Vaidya | October 21, 2015 | Print  |

LDR's ROI-C Cervical Cage has received FDA clearance for use with allograft.

Here are four points:


1. Previously, the ROI-C Cervical Cage was cleared only for use with autogenous bone graft.


2. LDR presented clinical literature review data to the FDA to investigate the risks and benefits associated with using allogenic bone graft with ROI-C.


3. The system is indicated for use in adult patients with degenerative disc disease of the cervical spine with accompanying radicular symptoms at one disc level from C2-T1.


4. LDR is a global medical device company focused on designing and commercializing proprietary surgical technologies for spinal treatments.


More articles on devices:
SeaSpine creates general counsel position: 5 things to know
IlluninOss Medical partners with Orthovactive
Amendia, Promimic enter into strategic venture: 4 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers